AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 530577: 2,6-Difluorobenzoic acid, tridecyl ester

Chemical compound data from PubChem database. IUPAC Name: tridecyl 2,6-difluorobenzoate. Molecular Formula: C20H30F2O2. Molecular Weight: 340.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526488: 2-Amino-5-chloro-2'-hydroxybenzophenone

Chemical compound data from PubChem database. IUPAC Name: (2-amino-5-chlorophenyl)-(2-hydroxyphenyl)methanone. Molecular Formula: C13H10ClNO2. Molecular Weight: 247.67. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NSDUH 2024 Methodological Resource Book (MRB)

Use this collection to provide context for estimates from the National Survey on Drug Use and Health (NSDUH). This collection includes materials used to conduct the survey, reports on how the survey was conducted, and reports on how the data were processed. The Statistical Inference Report details how the data were analyzed for reports and tables, which may be useful for data users looking to do their own analysis.New items are added to the collection as they become available, so resources published in a previous MRB may not yet be available for 2024. However, there are generally few changes from year to year, and a report from a previous year may have the information you are looking for.
NCHS - Leading Causes of Death: United States

This dataset presents the age-adjusted death rates for the 10 leading causes of death in the United States beginning in 1999.

Data are based on information from all resident death certificates filed in the 50 states and the District of Columbia using demographic and medical characteristics. Age-adjusted death rates (per 100,000 population) are based on the 2000 U.S. standard population. Populations used for computing death rates after 2010 are postcensal estimates based on the 2010 census, estimated as of July 1, 2010. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for non-census years before 2010 are revised using updated intercensal population estimates and may differ from rates previously published.

Causes of death classified by the International Classification of Diseases, Tenth Revision (ICD–10) are ranked according to the number of deaths assigned to rankable causes. Cause of death statistics are based on the underlying cause of death.

SOURCES
CDC/NCHS, National Vital Statistics System, mortality data (see http://www.cdc.gov/nchs/deaths.htm); and CDC WONDER (see http://wonder.cdc.gov).

REFERENCES

1. National Center for Health Statistics. Vital statistics data available. Mortality multiple cause files. Hyattsville, MD: National Center for Health Statistics. Available from: https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm.

2. Murphy SL, Xu JQ, Kochanek KD, Curtin SC, and Arias E. Deaths: Final data for 2015. National vital statistics reports; vol 66. no. 6. Hyattsville, MD: National Center for Health Statistics. 2017. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_06.pdf.
2010 CMHS Uniform Reporting System (URS) Output Tables for Pennsylvania

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2010. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Antitubercular therapy decreases nitric oxide production in HIV/TB coinfected patients

Background
          Nitric oxide (NO) production is increased among patients with human immunodeficiency virus (HIV) infection and also among those with tuberculosis (TB). In this study we sought to determine if there was increased NO production among patients with HIV/TB coinfection and the effect of four weeks chemotherapy on this level.
        
        
          Methods
          19 patients with HIV/TB coinfection were studied. They were treated with standard four drug antitubercular therapy and sampled at baseline and four weeks. 20 patients with HIV infection, but no opportunistic infections, were disease controls and 20 individuals were healthy controls. Nitrite and citrulline, surrogate markers for NO, were measured spectrophotometrically.
        
        
          Results
          The mean age of HIV/TB patients was 28.4 ± 6.8 years and CD4 count was 116 ± 36.6/mm. Mean nitrite level among HIV/TB coinfected was 207.6 ± 48.8 nmol/ml. This was significantly higher than 99.7 ± 26.5 nmol/ml, the value for HIV infected without opportunistic infections and 46.4 ± 16.2 nmol/ml, the value for healthy controls (p value < 0.01). The level of HIV/TB coinfected NO in patients declined to 144.5 ± 34.4 nmol/ml at four weeks of therapy (p value < 0.05). Mean citrulline among HIV/TB coinfected was 1446.8 ± 468.8 nmol/ml. This was significantly higher than 880.8 ± 434.8 nmol/ml, the value for HIV infected without opportunistic infections and 486.6 ± 212.5 nmol/ml, the value for healthy controls (p value < 0.01). Levels of citrolline in HIV/TB infected declined to 1116.2 ± 388.6 nmol/ml at four weeks of therapy (p value < 0.05).
        
        
          Conclusions
          NO production is elevated among patients with HIV infection, especially so among HIV/TB coinfected patients, but declines significantly following 4 weeks of antitubercular therapy.
AFCARS Report #13

This report provides preliminary estimaes of AFCARS data for FY 2005. Preliminary reports of AFCARS data include data received by September 30 for the report period ending March 31 and by March 31 for the report period ending September 30. This generally encompasses the required data submissions and submission of corrected data by States to avoid possible financial penalties.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E40067-T1: [Translated] HYDRAULIC IMPACT DEVICE.

A hydraulic striking device (1) includes a percussion piston (3) which reciprocates in an operating cylinder (2) and strikes a bit (4). The reciprocation is governed by a control valve (10) which is connected to the operating cylinder by a control conduit (27). A holding valve (30) in the control conduit has three connections (27a, 27b, 31): one with the control valve, one with the operating cylinder, and one with the return conduit (17). The connections (27a, 31) which are connected with the operating cylinder and with the control conduit are axially aligned and form the outlets of a hollow cavity (53) in which a preferably spherical movable valve body (54) is disposed, the cross-sectional area of the valve body being smaller than that of the cavity. The connection (27b) with the control valve opens radially into the cavity. If the valve body rests against the valve seat (55) which faces the return conduit, the axis of the connection (27b) passes through that half of the valve body which faces this valve seat. When the striking device operates, energy that is reflected from the bit to the percussion piston can be utilized for the following stroke and thus the total performance of the striking device is increased.
Program Instruction (PI-14-02)

This Program Instruction (PI) provides instruction on the availability of Federal Fiscal Year (FFY) 2014 funds under the Community-Based Grants for the Prevention of Child Abuse and Neglect program created by Title II of the Child Abuse Prevention and Treatment Act (CAPTA) as amended by Public Law (P.L.) 111-320.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E400857-T1: [Translated] METHOD AND DEVICE FOR SUPPRESSING A TRANSMISSION SIGNAL IN A RECEIVER OF AN RFID WRITING/READING DEVICE

A method and apparatus is disclosed for operating an RFID read/write unit with transmitting signal suppression. The RFID read/write unit comprises a radio frequency part including a transmitter and a receiver, and a baseband part based on digital signal processing. The method involves producing an amplitude and phase weighted copy of a transmitting signal, namely a compensation signal, with the baseband part. After linear modulation of the compensation signal, a resultant signal at an input of the receiver is subtracted in an addition stage from a spurious coupling signal. The transmitting signal has an auxiliary signal impressed upon a carrier signal from the RFID read/write unit with a frequency offset fd, for the purpose of processing without any DC voltage in the receiver downstream of an RX converter. The input of the receiver comprises a turn-on and turn-off attenuation element which protects the radio frequency part.
CCWIS Data Quality Plans Lessons Learned: Two Years after the CCWIS Transition

This webinar addressed critical topics for consideration by title IV-E agencies when writing data quality plans.  It discussed biennial review requirements and shared lessons learned (strengths and areas of improvement) from ACF's review and approval of data quality plans in the first two years after the CCWIS transition period.

Metadata-only record linking to the original dataset. Open original dataset below.
Roflumilast

ZORYVE is a prescription topical foam containing roflumilast (0.3%), a phosphodiesterase 4 inhibitor used to treat plaque psoriasis in adults. It reduces inflammation in the skin. Manufactured by Arcutis Biotherapeutics, Inc., and approved under NDA217242, it was launched in December 2023. This information was generated using AI and is provided for informational and research purposes only.
Simultaneous intra/extravascular administration of antiproliferative agents as a new strategy to inhibit restenosis: The peak of reactive cell proliferation as a hallmark for the duration of the treatment

Background
          Strictly intravascular approaches for the treatment of postangioplasty restenosis are effective in the intima and the inner parts of the media but may be insufficient to control redundant pathways in the more outer parts of the media and the adventitia. An inverse situation may occur subsequently to a strictly extravascular approach, like the recently suggested pericardial approach in pigs. We hypothesized that simultaneous intra/extravascular administration of anti-restenotic agents inhibits restenosis by blocking all stimulatory pathways in the entire arterial wall.
        
        
          Methods
          Fresh hearts of 25 domestic pigs were obtained from a local slaughterhouse. Left anterior descending coronary arteries (LAD) were harvested, cut into cylindric 5 mm segments, and cultured as ex vivo porcine organ cultures (POCs). After 9 bar ballooning simultaneous intra/extravascular administration of high dose diltiazem (50 μg/mL) was carried out for a period of 1, 2, 3, 4, 5, 6, and 7 days. At day 7 and 28 proliferative activity (BrdU), neointimal thickening, and staining against smooth muscle α-actin and vWF was analysed.
        
        
          Results
          7 days after ballooning administration of diltiazem for 4, 5, 6, and 7 days inhibited reactive cell proliferation by more than 50% (n.s.) as compared to control, 28 days after ballooning administration for 6 and 7 days inhibited neointimal thickening by more than 75% (p < 0.05). Simultaneous intra/extravascular administration of high dose diltiazem did not affect the expression of vWF in endothelial cells or smooth muscle α-actin in smooth muscle cells.
        
        
          Conclusions
          Simultaneous intra/extravascular administration of high dose diltiazem (50 μg/mL) has to be maintained for at least 6 days to achieve a significant inhibition of neointimal thickening. The data demonstrate the importance of the maximal reactive cell proliferation (= day 7 in the POC-model) for the calculation of the duration of the treatment period.
Prescribing patterns in premenstrual syndrome

Background
          Over 300 therapies have been proposed for premenstrual syndrome. To date there has been only one survey conducted in the UK of PMS treatments prescribed by GPs, a questionnaire-based study by the National Association of Premenstrual Syndrome in 1989. Since then, selective serotonin re-uptake inhibitors have been licensed for severe PMS/PMDD, and governmental recommendations to reduce the dosage of vitamin B6 (the first choice over-the-counter treatment for many women with PMS) have been made. This study investigates the annual rates of diagnoses and prescribing patterns for premenstrual syndrome (1993–1998) within a computerised general practitioner database.
        
        
          Methods
          Retrospective survey of prescribing data for premenstrual syndrome between 1993–1998 using the General Practice Research Database for the West Midlands Region which contains information on 282,600 female patients
        
        
          Results
          Overall the proportion of women with a prescription-linked diagnosis of premenstrual syndrome has halved over the five years. Progestogens including progesterone were the most commonly recorded treatment for premenstrual syndrome during the whole study period accounting for over 40% of all prescriptions. Selective serotonin-reuptake inhibitors accounted for only 2% of the prescriptions in 1993 but rose to over 16% by 1998, becoming the second most commonly recorded treatment. Vitamin B6 accounted for 22% of the prescriptions in 1993 but dropped markedly between 1997 and 1998 to 11%.
        
        
          Conclusions
          This study shows a yearly decrease in the number of prescriptions linked to diagnoses for premenstrual syndrome. Progestogens including progesterone, is the most widely prescribed treatment for premenstrual syndrome despite the lack of evidence demonstrating their efficacy.
Pregabalin

Pregabalin Extended Release is a generic prescription drug containing pregabalin, available as oral extended-release tablets in strengths of 82.5 mg, 165 mg, and 330 mg. Manufactured by ScieGen Pharmaceuticals under ANDA215675, it is a controlled substance (Schedule CV) that was marketed starting September 2022 but is now discontinued. This information was generated using AI and is provided for informational and research purposes only.
Nursing Home Cost Report (RHCF): 2022

The Nursing Home Cost Report (RHCF) is a uniform report completed by New York nursing homes to report income, expenses, assets, liabilities, and statistics to the Department of Health (DOH). Under DOH regulations (Part 86-2.2), nursing homes are required to file financial and statistical data with DOH annually. The data filed is part of the cost report and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends.
Patent AT-E399777-T1: [Translated] PYRROLE-2,5-DIONE DERIVATIVES AS MODULATORS OF THE LIVER-X RECEPTOR

Chemical patent from PubChem database. Patent Number: AT-E399777-T1. Title: Novel Pharmaceutical Composition. Filing Date: 1995-07-07. Inventors: Martinez, Carlos, Thompson, Emily. Abstract: The present invention relates to a novel pharmaceutical composition comprising one or more active pharmaceutical ingredients and pharmaceutically acce... IPC Classifications: C12N, C12P, A61K. This patent covers 36 claims related to 2 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Compound 529737: Dimethyl 2-chloro-4-bromo-3-oxopentanedioate

Chemical compound data from PubChem database. IUPAC Name: methyl 4-bromo-2-chloro-3-oxopent-4-enoate. Molecular Formula: C6H6BrClO3. Molecular Weight: 241.47. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
A new model for rheumatoid arthritis?

A chance observation has led to the development of a new murine model for inflammatory arthritis. Arthritis is induced, and transferred, by T-cell-dependent antibodies to glucose-6-phosphate isomerase. This enzyme is expressed in all cells, and is detectable in serum. There are several similarities to rheumatoid arthritis (RA) in the murine disease. This elegant model raises several questions as to how and why a systemic response focuses inflammation so strongly on synovial joints. The model also re-introduces the possibility that antibodies to widely expressed self-proteins may play a role in the pathogenesis of RA.
Compound 530247: 4-Methyl-1-propan-2-ylcyclohexane-1,3-diol

Chemical compound data from PubChem database. IUPAC Name: 4-methyl-1-propan-2-ylcyclohexane-1,3-diol. Molecular Formula: C10H20O2. Molecular Weight: 172.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530034: N-methoxy-17-[N-methoxy-C-(trimethylsilyloxymethyl)carbonimidoyl]-10,13-dimethyl-11,17-bis(trimethylsilyloxy)-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-imine

Chemical compound data from PubChem database. IUPAC Name: N-methoxy-17-[N-methoxy-C-(trimethylsilyloxymethyl)carbonimidoyl]-10,13-dimethyl-11,17-bis(trimethylsilyloxy)-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-imine. Molecular Formula: C32H62N2O5Si3. Molecular Weight: 639.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401668-T1: [Translated] CABLE TRANSFER FOR A SEMICONDUCTOR DETECTOR

The invention relates to a conductor crossover for a semiconductor detector, particularly for a drift detector for conducting X-ray spectroscopy. The conductor crossover comprises at least two doped semiconductor electrodes ( 2 ), which are placed inside a semiconductor substrate ( 1 ), at least one connecting conductor (M), which is guided over the semiconductor electrodes ( 2 ), and a first insulating layer (Ox). An intermediate electrode (L) is situated between the connecting conductor (M) and the first insulation layer (Ox). Said intermediate electrode overlaps the area of the semiconductor substrate ( 1 ) between the semiconductor electrodes ( 2 ) and is electrically insulated from the connecting conductor (M) by at least one additional insulation layer (I). The invention also relates to a drift detector equipped with a conductor crossover of this type and to a detector arrangement for conducting X-ray spectroscopy.
Eribulin mesylate

Eribulin Mesylate is a generic prescription drug used intravenously to treat certain cancers. It's a microtubule inhibitor that comes as a solution in single-dose vials (0.5 mg/mL strength). Manufactured by Hikma Pharmaceuticals USA Inc., it's approved under ANDA 218281. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E400891-T1: [Translated] METHOD FOR FORMING A SILICON EPITAXIAL LAYER

A silicon epitaxial layer is formed on the semiconductor underlayer of a target substrate (W) in the process chamber (2). This forming method includes a pressure reducing step of reducing the pressure inside the process chamber (2) accommodating the target substrate (W), a vapor phase growth step of introducing a film formation gas containing silane gas into the process chamber (2) to grow a silicon epitaxial layer on the semiconductor underlayer, and a hydrogen chloride treatment step and a hydrogen heat treatment step performed therebetween. The hydrogen chloride treatment step is arranged to introduce the first pre-treatment gas containing hydrogen chloride gas into the process chamber (2), thereby treating the atmosphere inside the process chamber (2). The hydrogen heat treatment step is arranged to introduce the second pre-treatment gas containing hydrogen gas into the process chamber (2), thereby treating the surface of the semiconductor underlayer. <IMAGE>
2010-2011 NSDUH National Maps of Prevalence Estimates by State

This report presents maps of State estimates for measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Results are provided by age group.
Compound 527685: Butanoic acid, 3-chloro, 1,2-dimethylpropyl ester

Chemical compound data from PubChem database. IUPAC Name: 3-methylbutan-2-yl 3-chlorobutanoate. Molecular Formula: C9H17ClO2. Molecular Weight: 192.68. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525710: p-Methoxybenzylidene-propyl-amine

Chemical compound data from PubChem database. IUPAC Name: 1-(4-methoxyphenyl)-N-propylmethanimine. Molecular Formula: C11H15NO. Molecular Weight: 177.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Elk Creek Seismic Waveforms 2009

Coal bursts (damaging seismic events in underground coal mines) pose a substantial threat to operations and mine workers. The underground coal mines in Colorado’s North Fork Valley (NFV) have experienced many coal bursts, often with distinct characteristics from those of other US coal mining regions. To better understand these events and manage their associated risks, the National Institute for Occupational Safety and Health undertook a long-term monitoring campaign at the Elk Creek Mine in the NFV. The monitoring efforts included a seismic network composed of both surface and underground sensors, borehole pressure cells (BPCs), instrumented support Cans, convergence monitors, ground condition surveys, and several other data sources. This dataset consists of the event waveform files from the seismic network for the 983,379 events that were detected during the monitoring campaign. The waveforms are stored in HDF5 files that are broken up by week. Within the HDF5 files, the data are organized by station id, event time, and channel. The amplitudes are velocity in meters/second.
 
This is download 1 of 49 and corresponds to the time range between November 8, 2009, and January 4, 2010.
Compound 526339: 2,6-Dibromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,7-dibromodibenzo-p-dioxin. Molecular Formula: C12H6Br2O2. Molecular Weight: 341.98. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
5.1 Clients in treatment, by primary focus of facility and facility operation: March 31, 2011. Number and percent distribution

This is a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing clients in treatment, by primary focus of facility and facility operation in 2011. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.